Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for FocalTherics (FOCL : NSDQ)

• Company Description    EDAP TMS S.A. develops, produces, markets and distributes minimally invasive medical devices, primarily for the treatment of urological diseases. They currently produce and market devices for treatment of benign prostate hyperplasia and urinary tract stones. They are also developing a third range of products for minimally invasive destruction of certain types of tumors. Number of Employees: 289

• Price / Volume Information    Yesterday's Closing Price: $6.03 Daily Weekly Monthly 20 Day Moving Average: 42,305 shares Shares Outstanding: 37.48 (millions) Market Capitalization: $226.02 (millions) Beta: -0.04 52 Week High: $6.18 52 Week Low: $1.21 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week 19.41% 18.53% 12 Week 81.63% 76.65% Year To Date 83.28% 71.04%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL Parc d'Activites la Poudrette-Lamartine 4/6 rue du Dauphine - Vaulx-en-Velin69120 VAULX EN VELIN,I0 69120 FRA ph: 33-04-72-15-31-50 fax: 33-04-72-15-31-51 jfraunces@lifesciadvisors.com http://www.edap-tms.com

• General Corporate Information    Officers Ryan Rhodes - Chief Executive Officer Lance Willsey - Chairman of the Board of Directors Kenneth Mobeck - Chief Financial Officer Francois Dietsch - Chief Accounting Officer Fran Schulz - Director Peer Information FocalTherics (ABMD) FocalTherics (DMDS) FocalTherics (CPWY.) FocalTherics (EQUR) FocalTherics (ECIA) FocalTherics (FMS) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED INSTRUMENTS Sector: Medical CUSIP: 268311107 SIC: 3845 Fiscal Year Fiscal Year End: December Last Reported Quarter: 03/01/26 Next Expected EPS Date: 08/27/26 Share - Related Items Shares Outstanding: 37.48 Most Recent Split Date: (:1) Beta: -0.04 Market Capitalization: $226.02 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $-0.22 Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $-0.78 Payout Ratio: Number of Estimates in the Fiscal Year Consensus: 1.00 Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: 08/27/26

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: 22.38 Price/Cash Flow: - Price / Sales: 3.04 EPS Growth vs. Year Ago Period: -20.00% vs. Previous Quarter: 4.00% Sales Growth vs. Year Ago Period: 24.73% vs. Previous Quarter: -18.59% ROE 06/30/26 - - 03/31/26 - -137.61 12/31/25 - -100.07 ROA 06/30/26 - - 03/31/26 - -40.62 12/31/25 - -37.38 Current Ratio 06/30/26 - - 03/31/26 - 1.34 12/31/25 - 1.54 Quick Ratio 06/30/26 - - 03/31/26 - 0.99 12/31/25 - 1.19 Operating Margin 06/30/26 - - 03/31/26 - -41.47 12/31/25 - -41.24 Net Margin 06/30/26 - - 03/31/26 - -41.47 12/31/25 - -41.24 Pre-Tax Margin 06/30/26 - - 03/31/26 - -40.95 12/31/25 - -40.85 Book Value 06/30/26 - - 03/31/26 - 0.27 12/31/25 - 0.52 Inventory Turnover 06/30/26 - - 03/31/26 - 2.77 12/31/25 - 2.43 Debt-to-Equity 06/30/26 - - 03/31/26 - 1.79 12/31/25 - 0.84 Debt-to-Capital 06/30/26 - - 03/31/26 - 64.11 12/31/25 - 45.58

Powered by Zacks Investment Research ©